RS65488B9 - Kombinacija regorafeniba i nivolumaba za lečenje karcinoma - Google Patents

Kombinacija regorafeniba i nivolumaba za lečenje karcinoma

Info

Publication number
RS65488B9
RS65488B9 RS20240481A RSP20240481A RS65488B9 RS 65488 B9 RS65488 B9 RS 65488B9 RS 20240481 A RS20240481 A RS 20240481A RS P20240481 A RSP20240481 A RS P20240481A RS 65488 B9 RS65488 B9 RS 65488B9
Authority
RS
Serbia
Prior art keywords
combination
regorafenib
limited
acid
treatment
Prior art date
Application number
RS20240481A
Other languages
English (en)
Serbian (sr)
Inventor
Sabine Hoff
Lars Röse
Dieter Zopf
Fabian Kiessling
Wiltrud Lederle
Dennis Doleschel
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of RS65488B1 publication Critical patent/RS65488B1/sr
Publication of RS65488B9 publication Critical patent/RS65488B9/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
RS20240481A 2017-06-02 2018-05-25 Kombinacija regorafeniba i nivolumaba za lečenje karcinoma RS65488B9 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17174169 2017-06-02
EP18725258.0A EP3630112B9 (en) 2017-06-02 2018-05-25 Combination of regorafenib and nivolumab for treating cancer
PCT/EP2018/063785 WO2018219807A1 (en) 2017-06-02 2018-05-25 Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Publications (2)

Publication Number Publication Date
RS65488B1 RS65488B1 (sr) 2024-05-31
RS65488B9 true RS65488B9 (sr) 2024-09-30

Family

ID=58992733

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20240481A RS65488B9 (sr) 2017-06-02 2018-05-25 Kombinacija regorafeniba i nivolumaba za lečenje karcinoma

Country Status (22)

Country Link
US (4) US11951166B2 (enExample)
EP (2) EP4342542A3 (enExample)
JP (3) JP7303122B2 (enExample)
KR (2) KR102843438B1 (enExample)
CN (3) CN117899212A (enExample)
AU (2) AU2018276273B2 (enExample)
BR (1) BR112019025478A8 (enExample)
CA (2) CA3244313A1 (enExample)
DK (1) DK3630112T3 (enExample)
ES (1) ES2978337T3 (enExample)
FI (1) FI3630112T3 (enExample)
HR (1) HRP20240551T1 (enExample)
HU (1) HUE066487T2 (enExample)
IL (2) IL270948B2 (enExample)
LT (1) LT3630112T (enExample)
MX (1) MX2023001721A (enExample)
PE (2) PE20242220A1 (enExample)
PL (1) PL3630112T3 (enExample)
PT (1) PT3630112T (enExample)
RS (1) RS65488B9 (enExample)
SI (1) SI3630112T1 (enExample)
WO (1) WO2018219807A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018276273B2 (en) 2017-06-02 2023-12-21 Bayer Healthcare Llc Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
CN111001004A (zh) * 2019-10-08 2020-04-14 广州医科大学附属第二医院 一种治疗肝癌的药物组合及其应用
WO2025117638A1 (en) * 2023-12-01 2025-06-05 Yale University Compositions and methods for treating cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2007054303A2 (en) 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl urea for treating diabetic neuropathy
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
AR092439A1 (es) * 2012-09-06 2015-04-22 Bayer Healthcare Llc Composicion farmaceutica recubierta que contiene regorafenib
MX357035B (es) * 2012-09-25 2018-06-25 Bayer Pharma AG Combinacion de regorafenib y acido acetilsalicilico para el tratamiento del cancer.
JP5653489B1 (ja) 2013-07-24 2015-01-14 三菱エンジニアリングプラスチックス株式会社 薄肉光学部材用ポリカーボネート樹脂ペレット及びその製造方法
EP3102605B1 (en) 2014-02-04 2018-11-14 Pfizer Inc Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
US20170165364A1 (en) 2014-02-21 2017-06-15 Idac Theranostics, Inc. Therapeutic agent for solid cancer
CA2954508A1 (en) * 2014-07-15 2016-01-21 Genentech, Inc. Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
AU2015289922A1 (en) 2014-07-15 2017-02-16 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
JP6698084B2 (ja) * 2014-08-08 2020-05-27 オンコクエスト インコーポレイテッドＯｎｃｏｑｕｅｓｔ Ｉｎｃ． がんのチェックポイント干渉療法の成績を高めるための腫瘍抗原特異的抗体およびｔｌｒ３刺激
KR20170042778A (ko) * 2014-08-19 2017-04-19 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 면역 세포의 기능 증강 방법 및 면역 세포의 다기능성 평가 방법
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
KR20170080697A (ko) 2014-11-13 2017-07-10 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
WO2016173959A1 (en) * 2015-04-28 2016-11-03 Bayer Pharma Aktiengesellschaft Regorafenib for treating colorectal cancer
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
JP2019517507A (ja) 2016-06-03 2019-06-24 イムクローン リミテッド ライアビリティ カンパニー 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
US10251888B2 (en) 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
AU2018276273B2 (en) 2017-06-02 2023-12-21 Bayer Healthcare Llc Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
WO2018226580A2 (en) * 2017-06-05 2018-12-13 Janssen Biotech, Inc. Antibodies that specifically bind pd-1 and methods of use

Also Published As

Publication number Publication date
EP4342542A3 (en) 2024-06-05
CN117899212A (zh) 2024-04-19
US11951166B2 (en) 2024-04-09
FI3630112T3 (fi) 2024-05-02
AU2023282197B2 (en) 2025-06-26
IL317015A (en) 2025-01-01
EP4342542A2 (en) 2024-03-27
AU2023282197A1 (en) 2024-01-04
US20200155674A1 (en) 2020-05-21
IL270948A (en) 2020-01-30
RU2019143599A (ru) 2021-07-09
EP3630112A1 (en) 2020-04-08
CN110662540B (zh) 2024-01-26
RU2019143599A3 (enExample) 2021-09-10
EP3630112B9 (en) 2024-06-26
CA3065125C (en) 2025-06-10
JP2022169780A (ja) 2022-11-09
JP2020521786A (ja) 2020-07-27
CA3065125A1 (en) 2018-12-06
US20200179354A1 (en) 2020-06-11
MX2023001721A (es) 2023-02-22
LT3630112T (lt) 2024-05-10
WO2018219807A1 (en) 2018-12-06
HUE066487T2 (hu) 2024-08-28
HRP20240551T1 (hr) 2024-07-05
US20200188372A1 (en) 2020-06-18
PE20200859A1 (es) 2020-08-25
KR102843438B1 (ko) 2025-08-06
KR20240091188A (ko) 2024-06-21
PL3630112T3 (pl) 2024-07-01
CN110662540A (zh) 2020-01-07
JP7475402B2 (ja) 2024-04-26
BR112019025478A2 (pt) 2020-06-23
DK3630112T3 (da) 2024-04-22
SI3630112T1 (sl) 2024-06-28
KR102673422B1 (ko) 2024-06-07
PT3630112T (pt) 2024-04-23
US20220133888A1 (en) 2022-05-05
US11517622B2 (en) 2022-12-06
CN117582495A (zh) 2024-02-23
AU2018276273B2 (en) 2023-12-21
BR112019025478A8 (pt) 2022-12-06
IL270948B1 (en) 2025-03-01
ES2978337T3 (es) 2024-09-10
CA3244313A1 (en) 2025-06-13
KR20200011971A (ko) 2020-02-04
AU2018276273A1 (en) 2019-12-12
PE20242220A1 (es) 2024-11-19
IL270948B2 (en) 2025-07-01
RS65488B1 (sr) 2024-05-31
EP3630112B1 (en) 2024-01-31
JP2024096905A (ja) 2024-07-17
JP7303122B2 (ja) 2023-07-04

Similar Documents

Publication Publication Date Title
EP2900269B1 (en) Combination of regorafenib and acetylsalicylic acid for treating colorectal cancer
AU2023282197B2 (en) Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
RU2774838C2 (ru) Комбинация регорафениба и ингибиторов pd-1/pd-l1(2) для лечения рака
BR122025015903A2 (pt) Combinação de regorafenib e inibidores de pd-1/pd-l1(2), seu uso, e kit para tratamento de distúrbios hiperproliferativos
HK40015063B (zh) 用於治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品
HK40015063A (en) Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer